What is the current North America Glucagon-like Peptide-1 Agonists Market size?

In 2024, the North America Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 6.94 billion. Read More

Who are the key players in North America Glucagon-like Peptide-1 Agonists Market?

Astrazeneca, Sanofi, Eli Lilly and Company, Pfizer Inc. and Novo Nordisk A/S are the major companies operating in the North America Glucagon-like Peptide-1 Agonists Market. Read More

What years does this North America Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the North America Glucagon-like Peptide-1 Agonists Market size was estimated at USD 6.99 billion. The report covers the North America Glucagon-like Peptide-1 Agonists Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

North America Glucagon-like Peptide-1 AgonistsCompanies

This report lists the top North America Glucagon-like Peptide-1 Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the North America Glucagon-like Peptide-1 Agonists industry.